---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018497"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:26:49.332045+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Azitra Q1 2024 net loss $2.9M; cash $3.0M; ATR-12/ATR-04 clinical updates

## Summary
- Q1 2024 net loss $2.9M vs $2.5M YoY; R&D and G&A each $1.5M vs $0.8M prior year.
- Cash and cash equivalents $3.0M as of 3/31/2024; raised $5.0M in Feb 2024 follow-on offering.
- ATR-12 Phase 1b trial activated sites, initial patients identified; safety data expected late 2024.
- ATR-04 pre-IND meeting completed; IND submission planned mid-2024 for Phase 1b in EGFRi rash.
- Bayer joint development agreement progresses; licensing agreement with upfront payment under discussion.

## SEC filing metadata
- accession: 0001493152-24-018497
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000149315224018497/0001493152-24-018497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000149315224018497/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018497
- JSON: https://secwatch.observer/filing/0001493152-24-018497.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018497.txt

## Key facts
- Earnings Releases
  Azitra, Inc. reported the quarter ended March 31, 2024 results: revenue $0, net income $2.9 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: $0
  - Net income: $2.9 million
  - Result: reported results
  source text: Financial Results for the Year Ended December 31, 2023 ● Service Revenue – Related Party : The Company generated $0 service revenue during the quarter ended March 31, 2024, compared to $113,300 for the comparable period in 2023. ● Research and Development (R&D) expenses : R&D expenses for the quarter ended March 31, 2024, were $1.5 million compared to $0.8 million for the comparable period in 2023. ● General and Administrative (G&A) expenses : G&A expenses for the quarter ended March 31, 2024, were $1.5 million compared to $0.8 million for the comparable period in 2023. ● Net Loss was $2.9 million for the quarter ended March 31, 2024, compared to $2.5 million for the comparable period in 2023. ● Cash and cash equivalents : As of March 31, 2024, the Company had cash and cash equivalents of $3.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701478/000149315224018497/0001493152-24-018497-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.